{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T06:47:03Z","timestamp":1790146023390,"version":"4.0.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T00:00:00Z","timestamp":1472083200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100012170","name":"Joseph and Silvana Melara Cancer Research Fund","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100012170","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s00228-016-2120-3","type":"journal-article","created":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T05:39:12Z","timestamp":1472103552000},"page":"1391-1399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate"],"prefix":"10.1007","volume":"72","author":[{"given":"Rehana","family":"Jamani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronak","family":"Saluja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"DeAngelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angie","family":"Giotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"Emmenegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,25]]},"reference":[{"issue":"2","key":"2120_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87\u2013108. doi: 10.3322\/caac.21262","journal-title":"CA Cancer J Clin"},{"issue":"30","key":"2120_CR2","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1200\/JCO.2013.54.8404","volume":"32","author":"E Basch","year":"2014","unstructured":"Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, Garrels K, Hotte S, Kattan MW, Raghavan D, Saad F, Taplin ME, Walker-Dilks C, Williams J, Winquist E, Bennett CL, Wootton T, Rumble RB, Dusetzina SB, Virgo KS (2014) Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 32(30):3436\u20133448. doi: 10.1200\/JCO.2013.54.8404","journal-title":"J Clin Oncol"},{"issue":"21","key":"2120_CR3","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS Bono de","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, Investigators C-A (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995\u20132005. doi: 10.1056\/NEJMoa1014618","journal-title":"N Engl J Med"},{"issue":"2","key":"2120_CR4","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138\u2013148. doi: 10.1056\/NEJMoa1209096","journal-title":"N Engl J Med"},{"issue":"18","key":"2120_CR5","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s40265-013-0150-z","volume":"73","author":"SM Hoy","year":"2013","unstructured":"Hoy SM (2013) Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer. Drugs 73(18):2077\u20132091. doi: 10.1007\/s40265-013-0150-z","journal-title":"Drugs"},{"issue":"6","key":"2120_CR6","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1517\/17425255.2015.1041918","volume":"11","author":"CS Han","year":"2015","unstructured":"Han CS, Patel R, Kim IY (2015) Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer. Expert Opin Drug Metab Toxicol 11(6):967\u2013975. doi: 10.1517\/17425255.2015.1041918","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2120_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0403-6","author":"GE Benoist","year":"2016","unstructured":"Benoist GE, Hendriks RJ, Mulders PF, Gerritsen WR, Somford DM, Schalken JA, van Oort IM, Burger DM, van Erp NP (2016) Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide. Clin Pharmacokinet DOI. doi: 10.1007\/s40262-016-0403-6","journal-title":"Clin Pharmacokinet DOI"},{"issue":"1","key":"2120_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/cpdd.132","volume":"4","author":"A Bernard","year":"2015","unstructured":"Bernard A, Vaccaro N, Acharya M, Jiao J, Monbaliu J, De Vries R, Stieltjes H, Yu M, Tran N, Chien C (2015) Impact on abiraterone pharmacokinetics and safety: open-label drug-drug interaction studies with ketoconazole and rifampicin. Clin Pharmacol Drug Dev 4(1):63\u201373. doi: 10.1002\/cpdd.132","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"2120_CR9","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/jcph.253","volume":"54","author":"T Marbury","year":"2014","unstructured":"Marbury T, Lawitz E, Stonerock R, Gonzalez M, Jiao J, Breeding J, Haqq C, Verboven P, Stieltjes H, Yu M, Molina A, Acharya M, Chien C, Tran N (2014) Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment. J Clin Pharmacol 54(7):732\u2013741. doi: 10.1002\/jcph.253","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"2120_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00280-012-2001-0","volume":"71","author":"KN Chi","year":"2013","unstructured":"Chi KN, Tolcher A, Lee P, Rosen PJ, Kollmannsberger CK, Papadopoulos KP, Patnaik A, Molina A, Jiao J, Pankras C, Kaiser B, Bernard A, Tran N, Acharya M (2013) Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol 71(1):237\u2013244. doi: 10.1007\/s00280-012-2001-0","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"2120_CR11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.1365-2796.2001.00892.x","volume":"250","author":"I Buajordet","year":"2001","unstructured":"Buajordet I, Ebbesen J, Erikssen J, Brors O, Hilberg T (2001) Fatal adverse drug events: the paradox of drug treatment. J Intern Med 250(4):327\u2013341","journal-title":"J Intern Med"},{"issue":"4","key":"2120_CR12","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1200\/JOP.2013.001183","volume":"10","author":"EM Segal","year":"2014","unstructured":"Segal EM, Flood MR, Mancini RS, Whiteman RT, Friedt GA, Kramer AR, Hofstetter MA (2014) Oral chemotherapy food and drug interactions: a comprehensive review of the literature. Journal of oncology practice \/ American Society of Clinical Oncology 10(4):e255\u2013e268. doi: 10.1200\/JOP.2013.001183","journal-title":"Journal of oncology practice \/ American Society of Clinical Oncology"},{"issue":"7","key":"2120_CR13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2174\/138920011796504527","volume":"12","author":"S Shi","year":"2011","unstructured":"Shi S, Klotz U (2011) Age-related changes in pharmacokinetics. Curr Drug Metab 12(7):601\u2013610","journal-title":"Curr Drug Metab"},{"issue":"3","key":"2120_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00228-012-1387-2","volume":"69","author":"RE Hubbard","year":"2013","unstructured":"Hubbard RE, O\u2019Mahony MS, Woodhouse KW (2013) Medication prescribing in frail older people. Eur J Clin Pharmacol 69(3):319\u2013326. doi: 10.1007\/s00228-012-1387-2","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"2120_CR15","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1016\/S1470-2045(14)70018-X","volume":"15","author":"JP Droz","year":"2014","unstructured":"Droz JP, Aapro M, Balducci L, Boyle H, Van den Broeck T, Cathcart P, Dickinson L, Efstathiou E, Emberton M, Fitzpatrick JM, Heidenreich A, Hughes S, Joniau S, Kattan M, Mottet N, Oudard S, Payne H, Saad F, Sugihara T (2014) Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 15(9):e404\u2013e414. doi: 10.1016\/S1470-2045(14)70018-X","journal-title":"Lancet Oncol"},{"issue":"12","key":"2120_CR16","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1038\/bjc.2014.531","volume":"111","author":"D Lorente","year":"2014","unstructured":"Lorente D, Omlin A, Ferraldeschi R, Pezaro C, Perez R, Mateo J, Altavilla A, Zafeirou Z, Tunariu N, Parker C, Dearnaley D, Gillessen S, de Bono J, Attard G (2014) Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. Br J Cancer 111(12):2248\u20132253. doi: 10.1038\/bjc.2014.531","journal-title":"Br J Cancer"},{"issue":"2","key":"2120_CR17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE, Investigators C-A (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152\u2013160. doi: 10.1016\/S1470-2045(14)71205-7","journal-title":"Lancet Oncol"},{"issue":"3","key":"2120_CR18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1517\/14740338.2013.784268","volume":"12","author":"E Carcelero","year":"2013","unstructured":"Carcelero E, Anglada H, Tuset M, Creus N (2013) Interactions between oral antineoplastic agents and concomitant medication: a systematic review. Expert Opin Drug Saf 12(3):403\u2013420. doi: 10.1517\/14740338.2013.784268","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"2120_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.critrevonc.2014.12.014","volume":"94","author":"F Ranchon","year":"2015","unstructured":"Ranchon F, Vial T, Rioufol C, Henin E, Falandry C, Freyer G, Trillet-Lenoir V, Le Tourneau C, You B (2015) Concomitant drugs with low risks of drug-drug interactions for use in oncology clinical trials. Crit Rev Oncol Hematol 94(2):189\u2013200. doi: 10.1016\/j.critrevonc.2014.12.014","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"2120_CR20","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1093\/annonc\/mdq761","volume":"22","author":"RW Leeuwen van","year":"2011","unstructured":"van Leeuwen RW, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG (2011) Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol 22(10):2334\u20132341. doi: 10.1093\/annonc\/mdq761","journal-title":"Ann Oncol"},{"issue":"5","key":"2120_CR21","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/bjc.2013.48","volume":"108","author":"RW Leeuwen van","year":"2013","unstructured":"van Leeuwen RW, Brundel DH, Neef C, van Gelder T, Mathijssen RH, Burger DM, Jansman FG (2013) Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer 108(5):1071\u20131078. doi: 10.1038\/bjc.2013.48","journal-title":"Br J Cancer"},{"issue":"5","key":"2120_CR22","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/annonc\/mdv029","volume":"26","author":"RW Leeuwen van","year":"2015","unstructured":"van Leeuwen RW, Jansman FG, van den Bemt PM, de Man F, Piran F, Vincenten I, Jager A, Rijneveld AW, Brugma JD, Mathijssen RH, van Gelder T (2015) Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol 26(5):992\u2013997. doi: 10.1093\/annonc\/mdv029","journal-title":"Ann Oncol"},{"issue":"5","key":"2120_CR23","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s11096-010-9410-0","volume":"32","author":"ML Voll","year":"2010","unstructured":"Voll ML, Yap KD, Terpstra WE, Crul M (2010) Potential drug-drug interactions between anti-cancer agents and community pharmacy dispensed drugs. Pharmacy world & science : PWS 32(5):575\u2013580. doi: 10.1007\/s11096-010-9410-0","journal-title":"Pharmacy world & science : PWS"},{"issue":"8","key":"2120_CR24","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.clinthera.2012.06.025","volume":"34","author":"Y Ko","year":"2012","unstructured":"Ko Y, Tan SL, Chan A, Wong YP, Yong WP, Ng RC, Lim SW, Salim A (2012) Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study. Clin Ther 34(8):1696\u20131704. doi: 10.1016\/j.clinthera.2012.06.025","journal-title":"Clin Ther"},{"issue":"13","key":"2120_CR25","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1200\/JCO.2014.58.7550","volume":"33","author":"G Nightingale","year":"2015","unstructured":"Nightingale G, Hajjar E, Swartz K, Andrel-Sendecki J, Chapman A (2015) Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol 33(13):1453\u20131459. doi: 10.1200\/JCO.2014.58.7550","journal-title":"J Clin Oncol"},{"issue":"10","key":"2120_CR26","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/nrd1851","volume":"4","author":"LC Wienkers","year":"2005","unstructured":"Wienkers LC, Heath TG (2005) Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 4(10):825\u2013833. doi: 10.1038\/nrd1851","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"2120_CR27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/bdd.1784","volume":"33","author":"G Camenisch","year":"2012","unstructured":"Camenisch G, Umehara K (2012) Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug-drug interactions. Biopharm Drug Dispos 33(4):179\u2013194. doi: 10.1002\/bdd.1784","journal-title":"Biopharm Drug Dispos"},{"issue":"4","key":"2120_CR28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3109\/03602532.2014.967866","volume":"46","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Sharma A, Shukla M, Vaghasiya K, Rangaraj N, Lal J (2014) Novel pre-clinical methodologies for pharmacokinetic drug-drug interaction studies: spotlight on \u201chumanized\u201d animal models. Drug Metab Rev 46(4):475\u2013493. doi: 10.3109\/03602532.2014.967866","journal-title":"Drug Metab Rev"},{"issue":"1","key":"2120_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/clpt.2009.198","volume":"87","author":"EL Olvey","year":"2010","unstructured":"Olvey EL, Clauschee S, Malone DC (2010) Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia. Clin Pharmacol Ther 87(1):48\u201351. doi: 10.1038\/clpt.2009.198","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2120_CR30","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2125.2006.02809.x","volume":"63","author":"AI Vitry","year":"2007","unstructured":"Vitry AI (2007) Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 63(6):709\u2013714. doi: 10.1111\/j.1365-2125.2006.02809.x","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"2120_CR31","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1345\/aph.1L255","volume":"42","author":"CM Wong","year":"2008","unstructured":"Wong CM, Ko Y, Chan A (2008) Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia. Ann Pharmacother 42(12):1737\u20131748. doi: 10.1345\/aph.1L255","journal-title":"Ann Pharmacother"},{"issue":"2","key":"2120_CR32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40264-014-0262-8","volume":"38","author":"RT Scheife","year":"2015","unstructured":"Scheife RT, Hines LE, Boyce RD, Chung SP, Momper JD, Sommer CD, Abernethy DR, Horn JR, Sklar SJ, Wong SK, Jones G, Brown ML, Grizzle AJ, Comes S, Wilkins TL, Borst C, Wittie MA, Malone DC (2015) Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support. Drug Saf 38(2):197\u2013206. doi: 10.1007\/s40264-014-0262-8","journal-title":"Drug Saf"},{"issue":"3","key":"2120_CR33","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1200\/JOP.2015.004002","volume":"11","author":"MK Krzyzanowska","year":"2015","unstructured":"Krzyzanowska MK, Powis M (2015) Extending the quality and safety agenda from parenteral to oral chemotherapy. Journal of oncology practice \/ American Society of Clinical Oncology 11(3):198\u2013201. doi: 10.1200\/JOP.2015.004002","journal-title":"Journal of oncology practice \/ American Society of Clinical Oncology"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2120-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-016-2120-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2120-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T03:59:09Z","timestamp":1589687949000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-016-2120-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,25]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["2120"],"URL":"https:\/\/doi.org\/10.1007\/s00228-016-2120-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,25]]}}}